4//SEC Filing
BIOS Fund III QP, LP 4
Accession 0001104659-23-074424
CIK 0001701478other
Filed
Jun 22, 8:00 PM ET
Accepted
Jun 23, 9:37 PM ET
Size
85.5 KB
Accession
0001104659-23-074424
Insider Transaction Report
Form 4
Azitra IncAZTR
BIOS Fund III QP, LP
10% Owner
Transactions
- Conversion
Common Stock
2023-06-21+25,280→ 137,000 total(indirect: Directly held by Bios Fund II NT, LP) - Conversion
Series B Convertible Preferred Stock
2023-06-21−123,718→ 0 total(indirect: Directly held by Bios Fund III, LP)→ Common Stock (123,718 underlying) - Conversion
Series B Convertible Preferred Stock
2023-06-21−170,272→ 0 total(indirect: Directly held by Bios Fund II QP, LP)→ Common Stock (170,272 underlying) - Conversion
Series B Convertible Preferred Stock
2023-06-21−22,798→ 0 total(indirect: Directly held by Bios Fund II NT, LP)→ Common Stock (22,798 underlying) - Conversion
Common Stock
2023-06-21+137,186→ 404,767 total(indirect: Directly held by Bios Fund III, LP) - Sale
Convertible Notes
2023-06-21−509,141→ 0 total(indirect: Directly held by Bios Fund III QP, LP) - Purchase
Common Stock
2023-06-21$5.00/sh+73,708$368,540→ 282,239 total(indirect: Directly held by Bios Fund III NT, LP) - Conversion
Common Stock
2023-06-21+799,467→ 799,467 total(indirect: Directly held by Bios Fund I, LP) - Conversion
Common Stock
2023-06-21+255,503→ 255,503 total(indirect: Directly held by Bios Fund II, LP) - Conversion
Common Stock
2023-06-21+436,173→ 436,173 total(indirect: Directly held by Bios Azitra Co-Invest I, LP) - Conversion
Common Stock
2023-06-21+188,810→ 1,023,442 total(indirect: Directly held by Bios Fund II QP, LP) - Conversion
Series B Convertible Preferred Stock
2023-06-21−130,498→ 0 total(indirect: Directly held by Bios Fund III NT, LP)→ Common Stock (130,498 underlying) - Conversion
Series A Convertible Preferred Stock
2023-06-21−799,467→ 0 total(indirect: Directly held by Bios Fund I, LP)→ Common Stock (799,467 underlying) - Purchase
Common Stock
2023-06-21+197,701→ 197,701 total(indirect: Directly held by Bios Fund III, LP) - Conversion
Series A-1 Convertible Preferred Stock
2023-06-21−101,842→ 0 total(indirect: Directly held by Bios Fund II NT, LP)→ Common Stock (101,842 underlying) - Sale
Convertible Notes
2023-06-21−77,953→ 0 total(indirect: Directly held by Bios Fund III, LP) - Purchase
Common Stock
2023-06-21$5.00/sh+456,412$2,282,060→ 1,747,670 total(indirect: Directly held by Bios Fund III QP, LP) - Purchase
Common Stock
2023-06-21+208,531→ 208,531 total(indirect: Directly held by Bios Fund III NT, LP) - Conversion
Common Stock
2023-06-21+467,613→ 467,613 total(indirect: Directly held by Bios Fund I QP, LP) - Purchase
Common Stock
2023-06-21$5.00/sh+69,880$349,400→ 267,581 total(indirect: Directly held by Bios Fund III, LP) - Purchase
Common Stock
2023-06-21+1,291,258→ 1,291,258 total(indirect: Directly held by Bios Fund III QP, LP) - Conversion
Common Stock
2023-06-21+896,035→ 2,643,705 total(indirect: Directly held by Bios Fund III QP, LP) - Sale
Convertible Notes
2023-06-21−82,223→ 0 total(indirect: Directly held by Bios Fund III NT, LP) - Conversion
Common Stock
2023-06-21+144,705→ 426,944 total(indirect: Directly held by Bios Fund III NT, LP) - Conversion
Series A-1 Convertible Preferred Stock
2023-06-21−412,389→ 0 total(indirect: Directly held by Bios Fund II QP, LP)→ Common Stock (412,389 underlying) - Conversion
Series A-1 Convertible Preferred Stock
2023-06-21−397,600→ 0 total(indirect: Directly held by Bios Azitra Co-Invest I, LP)→ Common Stock (397,600 underlying) - Conversion
Common Stock
2023-06-21+57,747→ 313,250 total(indirect: Directly held by Bios Fund II, LP) - Conversion
Common Stock
2023-06-21+834,632→ 834,632 total(indirect: Directly held by Bios Fund II QP, LP) - Conversion
Common Stock
2023-06-21+111,720→ 111,720 total(indirect: Directly held by Bios Fund II NT, LP) - Conversion
Series B Convertible Preferred Stock
2023-06-21−808,058→ 0 total(indirect: Directly held by Bios Fund III QP, LP)→ Common Stock (808,058 underlying) - Conversion
Series A Convertible Preferred Stock
2023-06-21−467,613→ 0 total(indirect: Directly held by Bios Fund I QP, LP)→ Common Stock (467,613 underlying) - Conversion
Series A-1 Convertible Preferred Stock
2023-06-21−232,908→ 0 total(indirect: Directly held by Bios Fund II, LP)→ Common Stock (232,908 underlying) - Conversion
Series B Convertible Preferred Stock
2023-06-21−52,078→ 0 total(indirect: Directly held by Bios Fund II, LP)→ Common Stock (52,078 underlying)
Holdings
- 13,106(indirect: By Trust)
Common Stock
- 135,808
Common Stock
- 13,106(indirect: By Trust)
Common Stock
BIOS Capital Management, LP
10% Owner
Transactions
- Conversion
Common Stock
2023-06-21+896,035→ 2,643,705 total(indirect: Directly held by Bios Fund III QP, LP) - Purchase
Common Stock
2023-06-21+208,531→ 208,531 total(indirect: Directly held by Bios Fund III NT, LP) - Conversion
Common Stock
2023-06-21+144,705→ 426,944 total(indirect: Directly held by Bios Fund III NT, LP) - Conversion
Common Stock
2023-06-21+799,467→ 799,467 total(indirect: Directly held by Bios Fund I, LP) - Conversion
Common Stock
2023-06-21+255,503→ 255,503 total(indirect: Directly held by Bios Fund II, LP) - Conversion
Common Stock
2023-06-21+834,632→ 834,632 total(indirect: Directly held by Bios Fund II QP, LP) - Conversion
Common Stock
2023-06-21+188,810→ 1,023,442 total(indirect: Directly held by Bios Fund II QP, LP) - Conversion
Series A Convertible Preferred Stock
2023-06-21−467,613→ 0 total(indirect: Directly held by Bios Fund I QP, LP)→ Common Stock (467,613 underlying) - Sale
Convertible Notes
2023-06-21−77,953→ 0 total(indirect: Directly held by Bios Fund III, LP) - Conversion
Common Stock
2023-06-21+436,173→ 436,173 total(indirect: Directly held by Bios Azitra Co-Invest I, LP) - Conversion
Series B Convertible Preferred Stock
2023-06-21−123,718→ 0 total(indirect: Directly held by Bios Fund III, LP)→ Common Stock (123,718 underlying) - Conversion
Series B Convertible Preferred Stock
2023-06-21−808,058→ 0 total(indirect: Directly held by Bios Fund III QP, LP)→ Common Stock (808,058 underlying) - Conversion
Series A-1 Convertible Preferred Stock
2023-06-21−232,908→ 0 total(indirect: Directly held by Bios Fund II, LP)→ Common Stock (232,908 underlying) - Sale
Convertible Notes
2023-06-21−509,141→ 0 total(indirect: Directly held by Bios Fund III QP, LP) - Purchase
Common Stock
2023-06-21+1,291,258→ 1,291,258 total(indirect: Directly held by Bios Fund III QP, LP) - Conversion
Series A Convertible Preferred Stock
2023-06-21−799,467→ 0 total(indirect: Directly held by Bios Fund I, LP)→ Common Stock (799,467 underlying) - Conversion
Series B Convertible Preferred Stock
2023-06-21−170,272→ 0 total(indirect: Directly held by Bios Fund II QP, LP)→ Common Stock (170,272 underlying) - Conversion
Series A-1 Convertible Preferred Stock
2023-06-21−101,842→ 0 total(indirect: Directly held by Bios Fund II NT, LP)→ Common Stock (101,842 underlying) - Conversion
Common Stock
2023-06-21+137,186→ 404,767 total(indirect: Directly held by Bios Fund III, LP) - Sale
Convertible Notes
2023-06-21−82,223→ 0 total(indirect: Directly held by Bios Fund III NT, LP) - Purchase
Common Stock
2023-06-21$5.00/sh+73,708$368,540→ 282,239 total(indirect: Directly held by Bios Fund III NT, LP) - Conversion
Common Stock
2023-06-21+467,613→ 467,613 total(indirect: Directly held by Bios Fund I QP, LP) - Conversion
Common Stock
2023-06-21+57,747→ 313,250 total(indirect: Directly held by Bios Fund II, LP) - Conversion
Common Stock
2023-06-21+111,720→ 111,720 total(indirect: Directly held by Bios Fund II NT, LP) - Conversion
Common Stock
2023-06-21+25,280→ 137,000 total(indirect: Directly held by Bios Fund II NT, LP) - Conversion
Series A-1 Convertible Preferred Stock
2023-06-21−412,389→ 0 total(indirect: Directly held by Bios Fund II QP, LP)→ Common Stock (412,389 underlying) - Conversion
Series B Convertible Preferred Stock
2023-06-21−22,798→ 0 total(indirect: Directly held by Bios Fund II NT, LP)→ Common Stock (22,798 underlying) - Conversion
Series A-1 Convertible Preferred Stock
2023-06-21−397,600→ 0 total(indirect: Directly held by Bios Azitra Co-Invest I, LP)→ Common Stock (397,600 underlying) - Purchase
Common Stock
2023-06-21+197,701→ 197,701 total(indirect: Directly held by Bios Fund III, LP) - Purchase
Common Stock
2023-06-21$5.00/sh+69,880$349,400→ 267,581 total(indirect: Directly held by Bios Fund III, LP) - Purchase
Common Stock
2023-06-21$5.00/sh+456,412$2,282,060→ 1,747,670 total(indirect: Directly held by Bios Fund III QP, LP) - Conversion
Series B Convertible Preferred Stock
2023-06-21−130,498→ 0 total(indirect: Directly held by Bios Fund III NT, LP)→ Common Stock (130,498 underlying) - Conversion
Series B Convertible Preferred Stock
2023-06-21−52,078→ 0 total(indirect: Directly held by Bios Fund II, LP)→ Common Stock (52,078 underlying)
Holdings
- 13,106(indirect: By Trust)
Common Stock
- 13,106(indirect: By Trust)
Common Stock
- 135,808
Common Stock
BIOS Advisors GP, LLC
10% Owner
Transactions
- Sale
Convertible Notes
2023-06-21−509,141→ 0 total(indirect: Directly held by Bios Fund III QP, LP) - Purchase
Common Stock
2023-06-21$5.00/sh+456,412$2,282,060→ 1,747,670 total(indirect: Directly held by Bios Fund III QP, LP) - Conversion
Common Stock
2023-06-21+144,705→ 426,944 total(indirect: Directly held by Bios Fund III NT, LP) - Sale
Convertible Notes
2023-06-21−82,223→ 0 total(indirect: Directly held by Bios Fund III NT, LP) - Conversion
Common Stock
2023-06-21+799,467→ 799,467 total(indirect: Directly held by Bios Fund I, LP) - Conversion
Common Stock
2023-06-21+57,747→ 313,250 total(indirect: Directly held by Bios Fund II, LP) - Conversion
Common Stock
2023-06-21+111,720→ 111,720 total(indirect: Directly held by Bios Fund II NT, LP) - Conversion
Common Stock
2023-06-21+25,280→ 137,000 total(indirect: Directly held by Bios Fund II NT, LP) - Conversion
Common Stock
2023-06-21+137,186→ 404,767 total(indirect: Directly held by Bios Fund III, LP) - Sale
Convertible Notes
2023-06-21−77,953→ 0 total(indirect: Directly held by Bios Fund III, LP) - Conversion
Common Stock
2023-06-21+436,173→ 436,173 total(indirect: Directly held by Bios Azitra Co-Invest I, LP) - Conversion
Series B Convertible Preferred Stock
2023-06-21−130,498→ 0 total(indirect: Directly held by Bios Fund III NT, LP)→ Common Stock (130,498 underlying) - Conversion
Common Stock
2023-06-21+896,035→ 2,643,705 total(indirect: Directly held by Bios Fund III QP, LP) - Conversion
Common Stock
2023-06-21+467,613→ 467,613 total(indirect: Directly held by Bios Fund I QP, LP) - Purchase
Common Stock
2023-06-21$5.00/sh+69,880$349,400→ 267,581 total(indirect: Directly held by Bios Fund III, LP) - Purchase
Common Stock
2023-06-21+197,701→ 197,701 total(indirect: Directly held by Bios Fund III, LP) - Purchase
Common Stock
2023-06-21+1,291,258→ 1,291,258 total(indirect: Directly held by Bios Fund III QP, LP) - Purchase
Common Stock
2023-06-21+208,531→ 208,531 total(indirect: Directly held by Bios Fund III NT, LP) - Conversion
Common Stock
2023-06-21+255,503→ 255,503 total(indirect: Directly held by Bios Fund II, LP) - Conversion
Common Stock
2023-06-21+188,810→ 1,023,442 total(indirect: Directly held by Bios Fund II QP, LP) - Conversion
Series A Convertible Preferred Stock
2023-06-21−799,467→ 0 total(indirect: Directly held by Bios Fund I, LP)→ Common Stock (799,467 underlying) - Conversion
Series B Convertible Preferred Stock
2023-06-21−52,078→ 0 total(indirect: Directly held by Bios Fund II, LP)→ Common Stock (52,078 underlying) - Conversion
Series B Convertible Preferred Stock
2023-06-21−170,272→ 0 total(indirect: Directly held by Bios Fund II QP, LP)→ Common Stock (170,272 underlying) - Conversion
Series A-1 Convertible Preferred Stock
2023-06-21−101,842→ 0 total(indirect: Directly held by Bios Fund II NT, LP)→ Common Stock (101,842 underlying) - Purchase
Common Stock
2023-06-21$5.00/sh+73,708$368,540→ 282,239 total(indirect: Directly held by Bios Fund III NT, LP) - Conversion
Common Stock
2023-06-21+834,632→ 834,632 total(indirect: Directly held by Bios Fund II QP, LP) - Conversion
Series B Convertible Preferred Stock
2023-06-21−123,718→ 0 total(indirect: Directly held by Bios Fund III, LP)→ Common Stock (123,718 underlying) - Conversion
Series A Convertible Preferred Stock
2023-06-21−467,613→ 0 total(indirect: Directly held by Bios Fund I QP, LP)→ Common Stock (467,613 underlying) - Conversion
Series A-1 Convertible Preferred Stock
2023-06-21−232,908→ 0 total(indirect: Directly held by Bios Fund II, LP)→ Common Stock (232,908 underlying) - Conversion
Series A-1 Convertible Preferred Stock
2023-06-21−412,389→ 0 total(indirect: Directly held by Bios Fund II QP, LP)→ Common Stock (412,389 underlying) - Conversion
Series B Convertible Preferred Stock
2023-06-21−22,798→ 0 total(indirect: Directly held by Bios Fund II NT, LP)→ Common Stock (22,798 underlying) - Conversion
Series A-1 Convertible Preferred Stock
2023-06-21−397,600→ 0 total(indirect: Directly held by Bios Azitra Co-Invest I, LP)→ Common Stock (397,600 underlying) - Conversion
Series B Convertible Preferred Stock
2023-06-21−808,058→ 0 total(indirect: Directly held by Bios Fund III QP, LP)→ Common Stock (808,058 underlying)
Holdings
- 13,106(indirect: By Trust)
Common Stock
- 135,808
Common Stock
- 13,106(indirect: By Trust)
Common Stock
Fletcher Aaron G.L.
10% Owner
Transactions
- Conversion
Common Stock
2023-06-21+896,035→ 2,643,705 total(indirect: Directly held by Bios Fund III QP, LP) - Purchase
Common Stock
2023-06-21+208,531→ 208,531 total(indirect: Directly held by Bios Fund III NT, LP) - Conversion
Common Stock
2023-06-21+834,632→ 834,632 total(indirect: Directly held by Bios Fund II QP, LP) - Conversion
Series B Convertible Preferred Stock
2023-06-21−808,058→ 0 total(indirect: Directly held by Bios Fund III QP, LP)→ Common Stock (808,058 underlying) - Conversion
Common Stock
2023-06-21+111,720→ 111,720 total(indirect: Directly held by Bios Fund II NT, LP) - Conversion
Common Stock
2023-06-21+436,173→ 436,173 total(indirect: Directly held by Bios Azitra Co-Invest I, LP) - Conversion
Series B Convertible Preferred Stock
2023-06-21−123,718→ 0 total(indirect: Directly held by Bios Fund III, LP)→ Common Stock (123,718 underlying) - Conversion
Series B Convertible Preferred Stock
2023-06-21−130,498→ 0 total(indirect: Directly held by Bios Fund III NT, LP)→ Common Stock (130,498 underlying) - Purchase
Common Stock
2023-06-21$5.00/sh+456,412$2,282,060→ 1,747,670 total(indirect: Directly held by Bios Fund III QP, LP) - Conversion
Series A Convertible Preferred Stock
2023-06-21−799,467→ 0 total(indirect: Directly held by Bios Fund I, LP)→ Common Stock (799,467 underlying) - Conversion
Series B Convertible Preferred Stock
2023-06-21−170,272→ 0 total(indirect: Directly held by Bios Fund II QP, LP)→ Common Stock (170,272 underlying) - Conversion
Series A-1 Convertible Preferred Stock
2023-06-21−397,600→ 0 total(indirect: Directly held by Bios Azitra Co-Invest I, LP)→ Common Stock (397,600 underlying) - Sale
Convertible Notes
2023-06-21−77,953→ 0 total(indirect: Directly held by Bios Fund III, LP) - Purchase
Common Stock
2023-06-21+197,701→ 197,701 total(indirect: Directly held by Bios Fund III, LP) - Purchase
Common Stock
2023-06-21$5.00/sh+69,880$349,400→ 267,581 total(indirect: Directly held by Bios Fund III, LP) - Sale
Convertible Notes
2023-06-21−509,141→ 0 total(indirect: Directly held by Bios Fund III QP, LP) - Purchase
Common Stock
2023-06-21$5.00/sh+73,708$368,540→ 282,239 total(indirect: Directly held by Bios Fund III NT, LP) - Conversion
Common Stock
2023-06-21+57,747→ 313,250 total(indirect: Directly held by Bios Fund II, LP) - Conversion
Series B Convertible Preferred Stock
2023-06-21−52,078→ 0 total(indirect: Directly held by Bios Fund II, LP)→ Common Stock (52,078 underlying) - Conversion
Series A-1 Convertible Preferred Stock
2023-06-21−101,842→ 0 total(indirect: Directly held by Bios Fund II NT, LP)→ Common Stock (101,842 underlying) - Conversion
Series B Convertible Preferred Stock
2023-06-21−22,798→ 0 total(indirect: Directly held by Bios Fund II NT, LP)→ Common Stock (22,798 underlying) - Conversion
Common Stock
2023-06-21+137,186→ 404,767 total(indirect: Directly held by Bios Fund III, LP) - Purchase
Common Stock
2023-06-21+1,291,258→ 1,291,258 total(indirect: Directly held by Bios Fund III QP, LP) - Conversion
Common Stock
2023-06-21+799,467→ 799,467 total(indirect: Directly held by Bios Fund I, LP) - Sale
Convertible Notes
2023-06-21−82,223→ 0 total(indirect: Directly held by Bios Fund III NT, LP) - Conversion
Common Stock
2023-06-21+144,705→ 426,944 total(indirect: Directly held by Bios Fund III NT, LP) - Conversion
Common Stock
2023-06-21+467,613→ 467,613 total(indirect: Directly held by Bios Fund I QP, LP) - Conversion
Common Stock
2023-06-21+255,503→ 255,503 total(indirect: Directly held by Bios Fund II, LP) - Conversion
Series A Convertible Preferred Stock
2023-06-21−467,613→ 0 total(indirect: Directly held by Bios Fund I QP, LP)→ Common Stock (467,613 underlying) - Conversion
Series A-1 Convertible Preferred Stock
2023-06-21−232,908→ 0 total(indirect: Directly held by Bios Fund II, LP)→ Common Stock (232,908 underlying) - Conversion
Series A-1 Convertible Preferred Stock
2023-06-21−412,389→ 0 total(indirect: Directly held by Bios Fund II QP, LP)→ Common Stock (412,389 underlying) - Conversion
Common Stock
2023-06-21+188,810→ 1,023,442 total(indirect: Directly held by Bios Fund II QP, LP) - Conversion
Common Stock
2023-06-21+25,280→ 137,000 total(indirect: Directly held by Bios Fund II NT, LP)
Holdings
- 13,106(indirect: By Trust)
Common Stock
- 135,808
Common Stock
- 13,106(indirect: By Trust)
Common Stock
BIOS Fund III NT, LP
10% Owner
Transactions
- Conversion
Common Stock
2023-06-21+896,035→ 2,643,705 total(indirect: Directly held by Bios Fund III QP, LP) - Sale
Convertible Notes
2023-06-21−82,223→ 0 total(indirect: Directly held by Bios Fund III NT, LP) - Sale
Convertible Notes
2023-06-21−509,141→ 0 total(indirect: Directly held by Bios Fund III QP, LP) - Purchase
Common Stock
2023-06-21$5.00/sh+73,708$368,540→ 282,239 total(indirect: Directly held by Bios Fund III NT, LP) - Conversion
Common Stock
2023-06-21+799,467→ 799,467 total(indirect: Directly held by Bios Fund I, LP) - Conversion
Series B Convertible Preferred Stock
2023-06-21−130,498→ 0 total(indirect: Directly held by Bios Fund III NT, LP)→ Common Stock (130,498 underlying) - Conversion
Series A Convertible Preferred Stock
2023-06-21−467,613→ 0 total(indirect: Directly held by Bios Fund I QP, LP)→ Common Stock (467,613 underlying) - Conversion
Series A-1 Convertible Preferred Stock
2023-06-21−232,908→ 0 total(indirect: Directly held by Bios Fund II, LP)→ Common Stock (232,908 underlying) - Purchase
Common Stock
2023-06-21$5.00/sh+456,412$2,282,060→ 1,747,670 total(indirect: Directly held by Bios Fund III QP, LP) - Conversion
Common Stock
2023-06-21+137,186→ 404,767 total(indirect: Directly held by Bios Fund III, LP) - Purchase
Common Stock
2023-06-21+1,291,258→ 1,291,258 total(indirect: Directly held by Bios Fund III QP, LP) - Purchase
Common Stock
2023-06-21+208,531→ 208,531 total(indirect: Directly held by Bios Fund III NT, LP) - Conversion
Common Stock
2023-06-21+834,632→ 834,632 total(indirect: Directly held by Bios Fund II QP, LP) - Conversion
Common Stock
2023-06-21+25,280→ 137,000 total(indirect: Directly held by Bios Fund II NT, LP) - Conversion
Series B Convertible Preferred Stock
2023-06-21−808,058→ 0 total(indirect: Directly held by Bios Fund III QP, LP)→ Common Stock (808,058 underlying) - Conversion
Series A-1 Convertible Preferred Stock
2023-06-21−397,600→ 0 total(indirect: Directly held by Bios Azitra Co-Invest I, LP)→ Common Stock (397,600 underlying) - Purchase
Common Stock
2023-06-21+197,701→ 197,701 total(indirect: Directly held by Bios Fund III, LP) - Conversion
Series B Convertible Preferred Stock
2023-06-21−123,718→ 0 total(indirect: Directly held by Bios Fund III, LP)→ Common Stock (123,718 underlying) - Sale
Convertible Notes
2023-06-21−77,953→ 0 total(indirect: Directly held by Bios Fund III, LP) - Purchase
Common Stock
2023-06-21$5.00/sh+69,880$349,400→ 267,581 total(indirect: Directly held by Bios Fund III, LP) - Conversion
Common Stock
2023-06-21+188,810→ 1,023,442 total(indirect: Directly held by Bios Fund II QP, LP) - Conversion
Series A Convertible Preferred Stock
2023-06-21−799,467→ 0 total(indirect: Directly held by Bios Fund I, LP)→ Common Stock (799,467 underlying) - Conversion
Series B Convertible Preferred Stock
2023-06-21−52,078→ 0 total(indirect: Directly held by Bios Fund II, LP)→ Common Stock (52,078 underlying) - Conversion
Common Stock
2023-06-21+255,503→ 255,503 total(indirect: Directly held by Bios Fund II, LP) - Conversion
Common Stock
2023-06-21+57,747→ 313,250 total(indirect: Directly held by Bios Fund II, LP) - Conversion
Series A-1 Convertible Preferred Stock
2023-06-21−412,389→ 0 total(indirect: Directly held by Bios Fund II QP, LP)→ Common Stock (412,389 underlying) - Conversion
Series B Convertible Preferred Stock
2023-06-21−170,272→ 0 total(indirect: Directly held by Bios Fund II QP, LP)→ Common Stock (170,272 underlying) - Conversion
Series A-1 Convertible Preferred Stock
2023-06-21−101,842→ 0 total(indirect: Directly held by Bios Fund II NT, LP)→ Common Stock (101,842 underlying) - Conversion
Series B Convertible Preferred Stock
2023-06-21−22,798→ 0 total(indirect: Directly held by Bios Fund II NT, LP)→ Common Stock (22,798 underlying) - Conversion
Common Stock
2023-06-21+144,705→ 426,944 total(indirect: Directly held by Bios Fund III NT, LP) - Conversion
Common Stock
2023-06-21+111,720→ 111,720 total(indirect: Directly held by Bios Fund II NT, LP) - Conversion
Common Stock
2023-06-21+467,613→ 467,613 total(indirect: Directly held by Bios Fund I QP, LP) - Conversion
Common Stock
2023-06-21+436,173→ 436,173 total(indirect: Directly held by Bios Azitra Co-Invest I, LP)
Holdings
- 13,106(indirect: By Trust)
Common Stock
- 135,808
Common Stock
- 13,106(indirect: By Trust)
Common Stock
BIOS Fund III, LP
10% Owner
Transactions
- Conversion
Common Stock
2023-06-21+57,747→ 313,250 total(indirect: Directly held by Bios Fund II, LP) - Conversion
Common Stock
2023-06-21+436,173→ 436,173 total(indirect: Directly held by Bios Azitra Co-Invest I, LP) - Conversion
Series B Convertible Preferred Stock
2023-06-21−808,058→ 0 total(indirect: Directly held by Bios Fund III QP, LP)→ Common Stock (808,058 underlying) - Conversion
Series B Convertible Preferred Stock
2023-06-21−52,078→ 0 total(indirect: Directly held by Bios Fund II, LP)→ Common Stock (52,078 underlying) - Conversion
Series A-1 Convertible Preferred Stock
2023-06-21−101,842→ 0 total(indirect: Directly held by Bios Fund II NT, LP)→ Common Stock (101,842 underlying) - Sale
Convertible Notes
2023-06-21−77,953→ 0 total(indirect: Directly held by Bios Fund III, LP) - Purchase
Common Stock
2023-06-21+197,701→ 197,701 total(indirect: Directly held by Bios Fund III, LP) - Conversion
Common Stock
2023-06-21+137,186→ 404,767 total(indirect: Directly held by Bios Fund III, LP) - Purchase
Common Stock
2023-06-21+1,291,258→ 1,291,258 total(indirect: Directly held by Bios Fund III QP, LP) - Conversion
Common Stock
2023-06-21+896,035→ 2,643,705 total(indirect: Directly held by Bios Fund III QP, LP) - Conversion
Common Stock
2023-06-21+799,467→ 799,467 total(indirect: Directly held by Bios Fund I, LP) - Purchase
Common Stock
2023-06-21+208,531→ 208,531 total(indirect: Directly held by Bios Fund III NT, LP) - Purchase
Common Stock
2023-06-21$5.00/sh+73,708$368,540→ 282,239 total(indirect: Directly held by Bios Fund III NT, LP) - Conversion
Common Stock
2023-06-21+144,705→ 426,944 total(indirect: Directly held by Bios Fund III NT, LP) - Conversion
Common Stock
2023-06-21+467,613→ 467,613 total(indirect: Directly held by Bios Fund I QP, LP) - Conversion
Series B Convertible Preferred Stock
2023-06-21−123,718→ 0 total(indirect: Directly held by Bios Fund III, LP)→ Common Stock (123,718 underlying) - Conversion
Series A Convertible Preferred Stock
2023-06-21−799,467→ 0 total(indirect: Directly held by Bios Fund I, LP)→ Common Stock (799,467 underlying) - Conversion
Series A-1 Convertible Preferred Stock
2023-06-21−232,908→ 0 total(indirect: Directly held by Bios Fund II, LP)→ Common Stock (232,908 underlying) - Conversion
Series B Convertible Preferred Stock
2023-06-21−170,272→ 0 total(indirect: Directly held by Bios Fund II QP, LP)→ Common Stock (170,272 underlying) - Purchase
Common Stock
2023-06-21$5.00/sh+456,412$2,282,060→ 1,747,670 total(indirect: Directly held by Bios Fund III QP, LP) - Conversion
Common Stock
2023-06-21+834,632→ 834,632 total(indirect: Directly held by Bios Fund II QP, LP) - Conversion
Common Stock
2023-06-21+111,720→ 111,720 total(indirect: Directly held by Bios Fund II NT, LP) - Conversion
Common Stock
2023-06-21+25,280→ 137,000 total(indirect: Directly held by Bios Fund II NT, LP) - Conversion
Series A-1 Convertible Preferred Stock
2023-06-21−412,389→ 0 total(indirect: Directly held by Bios Fund II QP, LP)→ Common Stock (412,389 underlying) - Conversion
Series B Convertible Preferred Stock
2023-06-21−22,798→ 0 total(indirect: Directly held by Bios Fund II NT, LP)→ Common Stock (22,798 underlying) - Conversion
Series A-1 Convertible Preferred Stock
2023-06-21−397,600→ 0 total(indirect: Directly held by Bios Azitra Co-Invest I, LP)→ Common Stock (397,600 underlying) - Purchase
Common Stock
2023-06-21$5.00/sh+69,880$349,400→ 267,581 total(indirect: Directly held by Bios Fund III, LP) - Sale
Convertible Notes
2023-06-21−509,141→ 0 total(indirect: Directly held by Bios Fund III QP, LP) - Sale
Convertible Notes
2023-06-21−82,223→ 0 total(indirect: Directly held by Bios Fund III NT, LP) - Conversion
Common Stock
2023-06-21+255,503→ 255,503 total(indirect: Directly held by Bios Fund II, LP) - Conversion
Series A Convertible Preferred Stock
2023-06-21−467,613→ 0 total(indirect: Directly held by Bios Fund I QP, LP)→ Common Stock (467,613 underlying) - Conversion
Common Stock
2023-06-21+188,810→ 1,023,442 total(indirect: Directly held by Bios Fund II QP, LP) - Conversion
Series B Convertible Preferred Stock
2023-06-21−130,498→ 0 total(indirect: Directly held by Bios Fund III NT, LP)→ Common Stock (130,498 underlying)
Holdings
- 13,106(indirect: By Trust)
Common Stock
- 13,106(indirect: By Trust)
Common Stock
- 135,808
Common Stock
BIOS Equity Partners III, LP
10% Owner
Transactions
- Conversion
Common Stock
2023-06-21+137,186→ 404,767 total(indirect: Directly held by Bios Fund III, LP) - Conversion
Common Stock
2023-06-21+834,632→ 834,632 total(indirect: Directly held by Bios Fund II QP, LP) - Conversion
Common Stock
2023-06-21+188,810→ 1,023,442 total(indirect: Directly held by Bios Fund II QP, LP) - Conversion
Common Stock
2023-06-21+436,173→ 436,173 total(indirect: Directly held by Bios Azitra Co-Invest I, LP) - Conversion
Series A Convertible Preferred Stock
2023-06-21−467,613→ 0 total(indirect: Directly held by Bios Fund I QP, LP)→ Common Stock (467,613 underlying) - Conversion
Series A-1 Convertible Preferred Stock
2023-06-21−232,908→ 0 total(indirect: Directly held by Bios Fund II, LP)→ Common Stock (232,908 underlying) - Conversion
Series B Convertible Preferred Stock
2023-06-21−52,078→ 0 total(indirect: Directly held by Bios Fund II, LP)→ Common Stock (52,078 underlying) - Conversion
Series A-1 Convertible Preferred Stock
2023-06-21−101,842→ 0 total(indirect: Directly held by Bios Fund II NT, LP)→ Common Stock (101,842 underlying) - Purchase
Common Stock
2023-06-21$5.00/sh+69,880$349,400→ 267,581 total(indirect: Directly held by Bios Fund III, LP) - Conversion
Common Stock
2023-06-21+111,720→ 111,720 total(indirect: Directly held by Bios Fund II NT, LP) - Conversion
Series A-1 Convertible Preferred Stock
2023-06-21−412,389→ 0 total(indirect: Directly held by Bios Fund II QP, LP)→ Common Stock (412,389 underlying) - Conversion
Series B Convertible Preferred Stock
2023-06-21−170,272→ 0 total(indirect: Directly held by Bios Fund II QP, LP)→ Common Stock (170,272 underlying) - Conversion
Series A-1 Convertible Preferred Stock
2023-06-21−397,600→ 0 total(indirect: Directly held by Bios Azitra Co-Invest I, LP)→ Common Stock (397,600 underlying) - Sale
Convertible Notes
2023-06-21−77,953→ 0 total(indirect: Directly held by Bios Fund III, LP) - Conversion
Common Stock
2023-06-21+144,705→ 426,944 total(indirect: Directly held by Bios Fund III NT, LP) - Conversion
Common Stock
2023-06-21+799,467→ 799,467 total(indirect: Directly held by Bios Fund I, LP) - Purchase
Common Stock
2023-06-21+1,291,258→ 1,291,258 total(indirect: Directly held by Bios Fund III QP, LP) - Purchase
Common Stock
2023-06-21$5.00/sh+456,412$2,282,060→ 1,747,670 total(indirect: Directly held by Bios Fund III QP, LP) - Sale
Convertible Notes
2023-06-21−82,223→ 0 total(indirect: Directly held by Bios Fund III NT, LP) - Purchase
Common Stock
2023-06-21$5.00/sh+73,708$368,540→ 282,239 total(indirect: Directly held by Bios Fund III NT, LP) - Purchase
Common Stock
2023-06-21+197,701→ 197,701 total(indirect: Directly held by Bios Fund III, LP) - Sale
Convertible Notes
2023-06-21−509,141→ 0 total(indirect: Directly held by Bios Fund III QP, LP) - Conversion
Common Stock
2023-06-21+896,035→ 2,643,705 total(indirect: Directly held by Bios Fund III QP, LP) - Purchase
Common Stock
2023-06-21+208,531→ 208,531 total(indirect: Directly held by Bios Fund III NT, LP) - Conversion
Common Stock
2023-06-21+467,613→ 467,613 total(indirect: Directly held by Bios Fund I QP, LP) - Conversion
Common Stock
2023-06-21+255,503→ 255,503 total(indirect: Directly held by Bios Fund II, LP) - Conversion
Common Stock
2023-06-21+57,747→ 313,250 total(indirect: Directly held by Bios Fund II, LP) - Conversion
Common Stock
2023-06-21+25,280→ 137,000 total(indirect: Directly held by Bios Fund II NT, LP) - Conversion
Series B Convertible Preferred Stock
2023-06-21−123,718→ 0 total(indirect: Directly held by Bios Fund III, LP)→ Common Stock (123,718 underlying) - Conversion
Series B Convertible Preferred Stock
2023-06-21−808,058→ 0 total(indirect: Directly held by Bios Fund III QP, LP)→ Common Stock (808,058 underlying) - Conversion
Series B Convertible Preferred Stock
2023-06-21−130,498→ 0 total(indirect: Directly held by Bios Fund III NT, LP)→ Common Stock (130,498 underlying) - Conversion
Series A Convertible Preferred Stock
2023-06-21−799,467→ 0 total(indirect: Directly held by Bios Fund I, LP)→ Common Stock (799,467 underlying) - Conversion
Series B Convertible Preferred Stock
2023-06-21−22,798→ 0 total(indirect: Directly held by Bios Fund II NT, LP)→ Common Stock (22,798 underlying)
Holdings
- 13,106(indirect: By Trust)
Common Stock
- 13,106(indirect: By Trust)
Common Stock
- 135,808
Common Stock
BIOS Azitra Co-Invest I, LP
10% Owner
Transactions
- Sale
Convertible Notes
2023-06-21−77,953→ 0 total(indirect: Directly held by Bios Fund III, LP) - Conversion
Series A Convertible Preferred Stock
2023-06-21−467,613→ 0 total(indirect: Directly held by Bios Fund I QP, LP)→ Common Stock (467,613 underlying) - Conversion
Series A-1 Convertible Preferred Stock
2023-06-21−232,908→ 0 total(indirect: Directly held by Bios Fund II, LP)→ Common Stock (232,908 underlying) - Conversion
Series B Convertible Preferred Stock
2023-06-21−130,498→ 0 total(indirect: Directly held by Bios Fund III NT, LP)→ Common Stock (130,498 underlying) - Conversion
Series A-1 Convertible Preferred Stock
2023-06-21−412,389→ 0 total(indirect: Directly held by Bios Fund II QP, LP)→ Common Stock (412,389 underlying) - Conversion
Series B Convertible Preferred Stock
2023-06-21−170,272→ 0 total(indirect: Directly held by Bios Fund II QP, LP)→ Common Stock (170,272 underlying) - Sale
Convertible Notes
2023-06-21−509,141→ 0 total(indirect: Directly held by Bios Fund III QP, LP) - Purchase
Common Stock
2023-06-21+1,291,258→ 1,291,258 total(indirect: Directly held by Bios Fund III QP, LP) - Sale
Convertible Notes
2023-06-21−82,223→ 0 total(indirect: Directly held by Bios Fund III NT, LP) - Purchase
Common Stock
2023-06-21$5.00/sh+73,708$368,540→ 282,239 total(indirect: Directly held by Bios Fund III NT, LP) - Conversion
Common Stock
2023-06-21+799,467→ 799,467 total(indirect: Directly held by Bios Fund I, LP) - Conversion
Common Stock
2023-06-21+436,173→ 436,173 total(indirect: Directly held by Bios Azitra Co-Invest I, LP) - Conversion
Common Stock
2023-06-21+111,720→ 111,720 total(indirect: Directly held by Bios Fund II NT, LP) - Conversion
Series B Convertible Preferred Stock
2023-06-21−52,078→ 0 total(indirect: Directly held by Bios Fund II, LP)→ Common Stock (52,078 underlying) - Conversion
Series B Convertible Preferred Stock
2023-06-21−22,798→ 0 total(indirect: Directly held by Bios Fund II NT, LP)→ Common Stock (22,798 underlying) - Conversion
Series A-1 Convertible Preferred Stock
2023-06-21−397,600→ 0 total(indirect: Directly held by Bios Azitra Co-Invest I, LP)→ Common Stock (397,600 underlying) - Conversion
Common Stock
2023-06-21+25,280→ 137,000 total(indirect: Directly held by Bios Fund II NT, LP) - Purchase
Common Stock
2023-06-21+197,701→ 197,701 total(indirect: Directly held by Bios Fund III, LP) - Purchase
Common Stock
2023-06-21$5.00/sh+69,880$349,400→ 267,581 total(indirect: Directly held by Bios Fund III, LP) - Conversion
Common Stock
2023-06-21+137,186→ 404,767 total(indirect: Directly held by Bios Fund III, LP) - Purchase
Common Stock
2023-06-21$5.00/sh+456,412$2,282,060→ 1,747,670 total(indirect: Directly held by Bios Fund III QP, LP) - Conversion
Common Stock
2023-06-21+896,035→ 2,643,705 total(indirect: Directly held by Bios Fund III QP, LP) - Purchase
Common Stock
2023-06-21+208,531→ 208,531 total(indirect: Directly held by Bios Fund III NT, LP) - Conversion
Common Stock
2023-06-21+467,613→ 467,613 total(indirect: Directly held by Bios Fund I QP, LP) - Conversion
Common Stock
2023-06-21+57,747→ 313,250 total(indirect: Directly held by Bios Fund II, LP) - Conversion
Series A-1 Convertible Preferred Stock
2023-06-21−101,842→ 0 total(indirect: Directly held by Bios Fund II NT, LP)→ Common Stock (101,842 underlying) - Conversion
Common Stock
2023-06-21+144,705→ 426,944 total(indirect: Directly held by Bios Fund III NT, LP) - Conversion
Common Stock
2023-06-21+255,503→ 255,503 total(indirect: Directly held by Bios Fund II, LP) - Conversion
Common Stock
2023-06-21+188,810→ 1,023,442 total(indirect: Directly held by Bios Fund II QP, LP) - Conversion
Common Stock
2023-06-21+834,632→ 834,632 total(indirect: Directly held by Bios Fund II QP, LP) - Conversion
Series B Convertible Preferred Stock
2023-06-21−808,058→ 0 total(indirect: Directly held by Bios Fund III QP, LP)→ Common Stock (808,058 underlying) - Conversion
Series A Convertible Preferred Stock
2023-06-21−799,467→ 0 total(indirect: Directly held by Bios Fund I, LP)→ Common Stock (799,467 underlying) - Conversion
Series B Convertible Preferred Stock
2023-06-21−123,718→ 0 total(indirect: Directly held by Bios Fund III, LP)→ Common Stock (123,718 underlying)
Holdings
- 13,106(indirect: By Trust)
Common Stock
- 135,808
Common Stock
- 13,106(indirect: By Trust)
Common Stock
Footnotes (7)
- [F1]The convertible note automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's initial public offering ("IPO") at a conversion price equal to $2.50 per share.
- [F2]Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I") and Bios Fund I QP, LP ("Bios Fund I QP"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Azitra Co-invest I, LP ("Bios Azitra Co-invest"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP.
- [F3]Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities.
- [F4]Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date
- [F5]Each share of Series A Convertible Preferred Stock automatically converted into one share of common stock of the Issuer upon the closing of the Issuer's IPO. The Series A Convertible Preferred Stock had no expiration date.
- [F6]Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.10 per share, after making certain anti-dilution adjustments. The Series A-1 Convertible Preferred Stock had no expiration date.
- [F7]Shares are held in a trust for the benefit of Mr. Fletcher's children. Mr. Fletcher and his spouse serve as the trustees of the trust.
Documents
Issuer
Azitra Inc
CIK 0001701478
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001791916
Filing Metadata
- Form type
- 4
- Filed
- Jun 22, 8:00 PM ET
- Accepted
- Jun 23, 9:37 PM ET
- Size
- 85.5 KB